They both need to protect their market share. I was a long MGI holder and know the history behind the drugs involed. Astex does not want to market drugs. They had a sales force and know its for them. JMO.
Celgene should buy s110 rights. Eiasi had the chance when Supergen could of been purchased for considerably less. Now they would pay nearly the same price for Astex as they did mgi. I would like to see Manuso advertise, looking for strategic offers. From Supergen shareholder point of view, Manuso and the board could of opted to payout dividends of nearly $ 8.5 since purchase. Share price would be at least $5 with dividend stream. Therefore $13.5 is break even for Supergen share holders.